Evidence map›Paper›PMID 31525357›Full record

ReviewChest2020

Meeting the Challenge of Identifying New Treatments for Type 2-Low Neutrophilic Asthma.

Or Kalchiem-Dekel, Xianglan Yao, Stewart J Levine

Abstract readReview
In one paragraph

Review in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. UnripeNutrients · 2023
    Article
  5. Gender dimorphism in IgA subclasses in T2-high asthma.Clinical and experimental medicine · 2023
    Article
  6. Severe Asthmatic Responses: The Impact of TSLP.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Biological therapy for severe asthma.Asthma research and practice · 2021
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Or Kalchiem-DekelLaboratory of Asthma and Lung Inflammation, Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Xianglan YaoLaboratory of Asthma and Lung Inflammation, Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Stewart J LevineLaboratory of Asthma and Lung Inflammation, Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Electronic address: levines@nhlbi.nih.gov.

Funding

Fiberoptic Bronchoscopy in Patients with AsthmaZIAHL006197 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVINE, STEWART · 2015 to 2024
$14.8M
Intramural NIH HHS ZIA HL006197
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Asthmatic AgentsAsthmaBiomarkersCytokinesEosinophilsHumansNeutrophilsAnti-Asthmatic AgentsBiomarkersCytokines

Identifiers

PMID31525357
PMCPMC6965689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.